Iman Ahmed, PharmD, BCOP, recently discussed the evidence for what’s actually contributing to health inequities in hematologic malignancies, and how providers can mitigate these disparities. Read More ›
Subgroup analyses presented at the American Society of Hematology (ASH) Annual Meeting San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Read More ›
